ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 723

Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up

Carolinne Monção1, Leticia Martins1, Marcela Penteado1, Rodrigo Reis2, Fabiana Miranda Moura dos Santos3, CRISTINA COSTA LANNA3, Antônio Luiz Ribeiro4 and Rosa Weiss Telles4, 1Hospital das Clinicas, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, 2Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, 3Medical School, Universidade Federal of Minas Gerais, Brazil, Belo Horizonte, Brazil, 4Medical School, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Co-morbidities, coronary artery disease, risk assessment and systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the incidence and variability of traditional coronary artery disease (CAD) risk factors in a cohort of systemic lupus erythematosus (SLE) patients.

Methods: 174 women were included (T0) in this prospective study on SLE atherosclerosis. The following traditional CAD risk factors were analyzed: hypertension (blood pressure ≥140/90 mmHg or antihypertensive medication), diabetes mellitus (DM) (fasting glucose ≥ 126mg/dl on at least two occasions or use of oral hypoglycemic agents or insulin), dyslipidemia (total-cholesterol ≥200mg/dl or HDL <40mg/dl or LDL ≥130mg/dl or use of oral lipid-lowering agents), hypertriglyceridemia (triglycerides ≥150mg/dl), obesity (body mass index ≥30kg/m2), abdominal obesity (waist circumference ≥88cm), smoking, positive family history for coronary event. Metabolic syndrome (MetS), according to Third Report of the NCEP/ATP III criteria, and Framingham risk score (FRS) were computed. The cumulative incidence between T0 and T1 for all risk factors was investigated. The incidence rate (person-years) for hypertension, DM, dyslipidemia and hypertriglyceridemia, with a CI95%, were calculated based in the data collected from the medical records. The frequency of risk factor disappearance at T1 (including the absence of treatment in the definition of disappearance), among patients with the risk factor at T0, was also described.

Results: The mean (SD) age at T0 of 151 patients reevaluated after 39 (36.5-42.0) months (T1) was 37.8 (11.1) years old, 75.5% non-white. The cumulative incidence, the incidence rate and the disappearance of some risk factors for CAD are presented in Table 1. The cumulative incidence during follow up were zero for smoking, 3.8% for positive family history for premature CAD, 16.5% for obesity, 18.8% for MetS and 39.1% for abdominal obesity. Eleven (11.7%) of 143 patients with low FRS in T0 were classified in high risk category in T1. Considering the risk factors disappearance, 26.0% with MetS at T0, 16.7% with obesity and 6.3% with abdominal obesity presented without the risk factor at T1. Only 1 (12.5%) patient within the higher risk of coronary event in 10 years (FRS>10%) at T0 “reduced” the risk to <10% in T1.

Conclusion: The authors identified a significant increase in the incidence of CAD risk factors in lupus patients with a follow-up of approximately 3 years. Conditions such as hypertension, obesity and DM presented less fluctuation than dyslipidemia between T0 and T1, raising considerations about the importance of statins use in lupus patients over time.

Table 1. Coronary artery disease risk factors cumulative incidence, incidence rate and disappearance after 39 (37-42) months, in lupus patients

Risk factor

Cumulative incidence*

Incidence rate

1000 person-years

(CI 95%)

Disappearance of risk factor**

Hypertension

18/79 (22.8%)

72.1 (38.8-105.4)

6/72 (8.3%)

Diabetes mellitus

5/143 (3.5%)

10.4 (1.3-19.5)

0

Dyslipidemia

33/89 (37.1%)

133.2 (87.8-178.6)

27/62 (43.5%)

LDL-c>130mg/dl

20/126 (15.9%)

49.9 (28.1-71.8)

9/25 (36.0%)

Total Chol>200mg/dl

27/122 (22.1%)

71.9 (44.8-99.0)

11/29 (37.9%)

HDL-c<40mg/dl

15/111 (13.5%)

44.2 (21.8-66.5)

27/40 (43.5%)

TGL>150mg/dl

16/108 (14.8%)

49.1 (25.0-73.1)

18/30 (41.9%)

*Incident case/Number of patients without risk factor at T0.

**Number of patients with disappearance of a risk factor/Number of patients with the risk factor at T0.


Disclosure: C. Monção, None; L. Martins, None; M. Penteado, None; R. Reis, None; F. M. M. dos Santos, None; C. C. LANNA, None; A. L. Ribeiro, None; R. W. Telles, None.

To cite this abstract in AMA style:

Monção C, Martins L, Penteado M, Reis R, dos Santos FMM, LANNA CC, Ribeiro AL, Telles RW. Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/incidence-and-variability-of-cardiovascular-risk-factors-in-female-lupus-patients-a-3-year-follow-up/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-variability-of-cardiovascular-risk-factors-in-female-lupus-patients-a-3-year-follow-up/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology